Danaher Corporation (DHR)
NYSEHealth CareDiagnostics & ResearchSnapshot 2026-07-07
$194.18+0.29%
Close 2026-07-07 · 1-day change
Reading DHR? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track DHR free→NYSEHealth CareDiagnostics & ResearchSnapshot 2026-07-07
Reading DHR? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track DHR free→Warn: Management is running behind on a stated commitment.
Danaher grows revenue 3% to 6% yearly. Profit per share is rising, with guidance at $8.45 for 2026. The company buys back shares, showing strong capital use. Its quality score improved significantly.
Revenue growth lags the 3% to 6% target. Profit growth may slow given soft guidance. Capital obligations and volatile management raise risks.
The price is about 2% below our fair value near $197. Analysts expect 9% revenue growth, which is above management's 3% to 6% target. Our fair value is 14% below the Street median, reflecting more cautious growth assumptions.
Breaks if: Adjusted EPS guidance falls below $8.35 for FY26
Danaher has increased its full year adjusted diluted EPS guidance to $8.35 to $8.55.
Standing thesis, reviewed periodically — not a price target or advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated in 4 of last 4 quarters. Net earnings per diluted share increased from $1.32 in 2025-Q1 to $1.45 in 2026-Q1, supporting the raised EPS guidance of $8.35 to $8.55 for the full year. The trajectory is on track with the guidance increase.
“The Company is also increasing its full year adjusted diluted net earnings per common share guidance to a range of $8.35 to $8.55.”
“the Company is also increasing its full year adjusted diluted net earnings per common share guidance to a range of $8.35 to $8.55 versus previous guidance of $8.35 to $8.50.”
“anticipated non-GAAP adjusted diluted net earnings per common share is expected to be toward the high-end of our previously announced guidance range of $7.70 to $7.80.”
“the Company is maintaining its full year adjusted diluted net earnings per common share guidance range of $7.70 to $7.80.”
Breaks if: No share buyback activity announced or executed in next 12 months
Danaher announced a share buyback program as part of its capital allocation strategy.
Breaks if: YoY revenue growth falls below 3% in FY26
Danaher aims to increase non-GAAP core revenue by 3% to 6% year-over-year for 2026.
Stated in 4 of last 4 quarters. Revenues increased 3.5% year-over-year to $6.0 billion in 2026-Q1, aligning with the lower end of the 3% to 6% growth target. The trajectory shows limited progress towards the upper range of the target.
“The Company continues to expect that non-GAAP core revenue will increase in the 3% to 6% range year-over-year.”
“For full year 2026, the Company expects that non-GAAP core revenue will increase in the 3% to 6% range year-over-year.”
“For full year 2025, anticipated non-GAAP core revenue will grow low-single digits year-over-year.”
“non-GAAP core revenue will grow low-single digits year-over-year for the full year 2025.”